We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+13.84%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$643M
AUM Growth
+$6.63M
Cap. Flow
-$4.29M
Cap. Flow %
-0.67%
Top 10 Hldgs %
65.7%
Holding
52
New
6
Increased
8
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$35.8M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$32.1M
3
COGT icon
Cogent Biosciences
COGT
+$12.7M
4
PHVS icon
Pharvaris
PHVS
+$11.3M
5
DFTX
Definium Therapeutics
DFTX
+$6.02M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$36.5M
2
INSM icon
Insmed
INSM
+$15.7M
3
TERN
Terns Pharmaceuticals
TERN
+$9.29M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.02M
5
ANTX icon
AN2 Therapeutics
ANTX
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 97.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$86.7M 13.49%
3,006,980
+126,100
+4% +$4.67M
VRNA
2
DELISTED
Verona Pharma
VRNA
$52.8M 8.21%
1,835,200
-60,000
-3% -$1.48M
GPCR icon
3
Structure Therapeutics
GPCR
$3.49B
$52.6M 8.18%
1,198,000
+57,940
+5% +$2.24M
DNTH icon
4
Dianthus Therapeutics
DNTH
$5.68B
$47.8M 7.44%
1,746,667
– –
AVBP icon
5
ArriVent BioPharma
AVBP
$1.48B
$46.4M 7.22%
1,976,387
+173,083
+10% +$3.93M
CNTA
6
DELISTED
Centessa Pharmaceuticals
CNTA
$32.2M 5%
2,012,052
-333,023
-14% -$4.08M
INSM icon
7
Insmed
INSM
$23.2B
$31.9M 4.96%
436,820
-213,396
-33% -$15.7M
NUVB icon
8
Nuvation Bio
NUVB
$2.24B
$27.9M 4.34%
12,171,513
+11,739,913
+2,720% +$35.8M
CRBP icon
9
Corbus Pharmaceuticals
CRBP
$170M
$23M 3.58%
1,115,000
+627,000
+128% +$32.1M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.86B
$21.1M 3.28%
2,425,000
– –
VRDN icon
11
Viridian Therapeutics
VRDN
$2.13B
$19.8M 3.08%
870,000
+250,000
+40% +$4.09M
CATX icon
12
Perspective Therapeutics
CATX
$332M
$19M 2.95%
1,422,224
-158,025
-10% -$2.1M
INSM icon
13
CALL
Insmed
INSM
$23.2B
$18.3M 2.84%
250,000
– –
DFTX
14
Definium Therapeutics
DFTX
$5.73B
$17.2M 2.67%
3,018,000
+865,000
+40% +$6.02M
COGT icon
15
Cogent Biosciences
COGT
$6.79B
$14.1M 2.19%
+1,305,000
New +$12.7M
BBIO icon
16
BridgeBio Pharma
BBIO
$16.5B
$14.1M 2.19%
552,000
-138,000
-20% -$3.62M
PHVS icon
17
Pharvaris
PHVS
$2.39B
$11.5M 1.79%
+620,470
New +$11.3M
DYN icon
18
Dyne Therapeutics
DYN
$4.04B
$9.44M 1.47%
262,726
-918,072
-78% -$36.5M
TSHA icon
19
Taysha Gene Therapies
TSHA
$1.59B
$9.19M 1.43%
4,572,222
– –
GOSS icon
20
Gossamer Bio
GOSS
$66.5M
$9.06M 1.41%
9,187,883
– –
KLRS
21
Kalaris Therapeutics
KLRS
$88.7M
$9.06M 1.41%
487,043
+60,956
+14% +$1.07M
EYPT icon
22
EyePoint Inc
EYPT
$1.02B
$8.74M 1.36%
1,093,503
– –
PRAX icon
23
Praxis Precision Medicines
PRAX
$9.07B
$7.48M 1.16%
130,000
-130,000
-50% -$7.02M
MLYS icon
24
Mineralys Therapeutics
MLYS
$2.35B
$7.27M 1.13%
600,000
– –
RGLS
25
DELISTED
Regulus Therapeutics
RGLS
$6.69M 1.04%
4,263,701
– –
1
2 3

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Octagon Capital Advisors held 52 positions worth $643M, up 1% from $636M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Octagon Capital Advisors's Q3 2024 filing shows 6 new, 8 increased, 9 reduced and 10 closed positions. Its largest new stake was Cogent Biosciences: 1,305,000 shares worth $14.1M. The largest sale was Dyne Therapeutics, an estimated $36.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

  • Octagon Capital Advisors's largest Q3 2024 buy was Cogent Biosciences: 1,305,000 shares worth $14.1M.
  • Octagon Capital Advisors added most to Nuvation Bio in Q3 2024, an estimated $35.8M increase.
  • Octagon Capital Advisors's biggest Q3 2024 reduction was Dyne Therapeutics, cutting an estimated $36.5M.
  • Octagon Capital Advisors fully exited Terns Pharmaceuticals in Q3 2024, selling an estimated $9.29M.
  • Octagon Capital Advisors's ten largest holdings make up 66% of its $643M portfolio in Q3 2024.
  • Octagon Capital Advisors opened 6 new positions and closed 10 in Q3 2024.
  • Octagon Capital Advisors's portfolio value rose 1% quarter-over-quarter to $643M.

Based on Octagon Capital Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.